Project description:Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in natural history reflects unrecognized molecular heterogeneity in the tumors. Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies. Here we show that there is diversity in gene expression among the tumors of DLBCL patients, apparently reflecting the variation in tumor proliferation rate, host response and differentiation state of the tumor. We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation. One type expressed genes characteristic of germinal center B cells ('germinal center B-like DLBCL'); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells ('activated B-like DLBCL'). Patients with germinal center B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL. The molecular classification of tumors on the basis of gene expression can thus identify previously undetected and clinically significant subtypes of cancer. This study is described more fully in Alizadeh AA et al.(2000) Nature 403:503-11

2002-06-27 | E-GEOD-60 | biostudies-arrayexpress

Human Diffuse large B cell lymphoma cell lines

Project description:We have analyzed by label free mass spectrometry the whole cells and secreted extracellular vesicles (EVs) proteomes of two different molecular subtypes of DLBCL, germinal center B cell (GCB subtype) and activated B cell (ABC subtype). Cell line: OCI-Ly3 (ABC) O3_2.raw O3_1.raw O2_2.raw O2_1.raw O1_2.raw O1_1.raw Cell line: HT (GCB) H4_2.raw H4_1.raw H3_2.raw H3_1.raw H2_2.raw H2_1.raw H1_2.raw H1_1.raw EVs OCI-Ly3 eO2_2.raw eO2_1.raw eO2.raw eO1_2.raw eO1_1.raw eO1.raw EVs HT eH2_2.raw eH2_1.raw eH2.raw eH1_2.raw eH1_1.raw eH1.raw EVs cell line RIVA: D3_2.raw D3_1.raw D2_2.raw D2_1.raw D1_2.raw D1_1.raw EVs cell line DB: C3_2.raw C3_1.raw C2_2.raw C2_1.raw C1_2.raw C1_1.raw Cell line: RIVA (ABC) B3_2.raw B3_1.raw B2_2.raw B2_1.raw B1_2.raw B1_1.raw Cell line: DB (GCB) A3_2.raw A3_1.raw A2_2.raw A2_1.raw A1_2.raw A1_1.raw

2021-11-04 | PXD028267 | Pride

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma.

Project description: Not available

| S-EPMC9851376 | biostudies-literature

Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.

Project description: Not available

| S-EPMC10837180 | biostudies-literature